Research Topic

Role of Radiotherapy in the Era of Targeted Therapy and Precision Oncology

About this Research Topic

In recent decades, cancer therapeutic strategies have greatly benefited from genomic and molecular characterization of tumors and technological innovations that have allowed more personalized approaches. For example, novel small molecule inhibitors, such as dabrafenib, have changed the treatment landscape for BRAF-mutant tumors, or anti-HER2 antibodies, such as trastuzumab, have revolutionized the treatment for HER2-positive breast cancer. Immune checkpoint blockade with anti-CTLA4, anti-PD-1, and/or anti-PD-L1 have recently been shown to improve outcomes in many diverse cancer subtypes by reactivating patients’ immune response. CAR T-cell therapy is another form of immunotherapy that has revolutionized treatment for hematologic malignancies. On the other hand, local control with surgery and radiotherapy remains critical for long-term outcomes in many diverse cancer subtypes. With the advent of these novel systemic therapies, the cancer treatment paradigm is changing and increasingly personalized to molecular or genomic information from the patient’s tumor. While new preclinical and clinical studies have already begun to investigate the role of radiotherapy in this ever changing landscape, the role of radiotherapy within novel treatment paradigms incorporating targeted therapy remains not well defined or understood.

This Research Topic aims to capture the most up-to-date and relevant research, commentary, and review of the changes in radiotherapy treatment paradigm in the era of targeted inhibitors, immunotherapy, and CAR T-cell therapy.

We welcome laboratory, translational, and clinical studies that explore the intersection of radiotherapy and novel systemic therapy options, including, but not limited to:

• Basic or translational research studies including radiobiology and in vivo imaging that investigate the role of radiosensitizers or concurrent radioimmunology to tackle diverse cancer types
• Clinical studies that examine the safety and/or efficacy of combination radiation with novel targeted therapy, including, but not limited to, small molecular inhibitors, immune checkpoint blockade, or CAR T-cell therapy
• Review articles or commentary on future cancer treatment paradigms incorporating radiotherapy in the era of precision oncology, including clinical trial design


Keywords: radiotherapy, targeted therapy, immunotherapy, radiosensitizers, precision oncology


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

In recent decades, cancer therapeutic strategies have greatly benefited from genomic and molecular characterization of tumors and technological innovations that have allowed more personalized approaches. For example, novel small molecule inhibitors, such as dabrafenib, have changed the treatment landscape for BRAF-mutant tumors, or anti-HER2 antibodies, such as trastuzumab, have revolutionized the treatment for HER2-positive breast cancer. Immune checkpoint blockade with anti-CTLA4, anti-PD-1, and/or anti-PD-L1 have recently been shown to improve outcomes in many diverse cancer subtypes by reactivating patients’ immune response. CAR T-cell therapy is another form of immunotherapy that has revolutionized treatment for hematologic malignancies. On the other hand, local control with surgery and radiotherapy remains critical for long-term outcomes in many diverse cancer subtypes. With the advent of these novel systemic therapies, the cancer treatment paradigm is changing and increasingly personalized to molecular or genomic information from the patient’s tumor. While new preclinical and clinical studies have already begun to investigate the role of radiotherapy in this ever changing landscape, the role of radiotherapy within novel treatment paradigms incorporating targeted therapy remains not well defined or understood.

This Research Topic aims to capture the most up-to-date and relevant research, commentary, and review of the changes in radiotherapy treatment paradigm in the era of targeted inhibitors, immunotherapy, and CAR T-cell therapy.

We welcome laboratory, translational, and clinical studies that explore the intersection of radiotherapy and novel systemic therapy options, including, but not limited to:

• Basic or translational research studies including radiobiology and in vivo imaging that investigate the role of radiosensitizers or concurrent radioimmunology to tackle diverse cancer types
• Clinical studies that examine the safety and/or efficacy of combination radiation with novel targeted therapy, including, but not limited to, small molecular inhibitors, immune checkpoint blockade, or CAR T-cell therapy
• Review articles or commentary on future cancer treatment paradigms incorporating radiotherapy in the era of precision oncology, including clinical trial design


Keywords: radiotherapy, targeted therapy, immunotherapy, radiosensitizers, precision oncology


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

17 July 2020 Abstract
30 November 2020 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

17 July 2020 Abstract
30 November 2020 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..